Literature DB >> 6974386

A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent otitis media.

P H Mäkelä, M Leinonen, J Pukander, P Karma.   

Abstract

A total of 827 infants and children three months to six years of age were vaccinated randomly after an attack of otitis media, with either the 14-valent pneumococcal vaccine or a control vaccine against Hemophilus influenzae type b. Clinically acute attacks of otitis media that occurred greater than or equal to 14 days after vaccination were analyzed by culture of the middle ear fluid. Children who had received the pneumococcal vaccine at the age of seven to 83 months experienced within the first six months after vaccination significantly fewer attacks of otitis media caused by Streptococcus pneumoniae than did children in the control group (50% overall reduction, p less than 0.01). The reduction of attacks was specific to those pneumococcal types/groups present in the vaccine that induced a good serum antibody response; the specific protection indicated for vaccine types/groups other than 6 (to which the antibody response was very poor) was 67% (P less than 0.001). No or very little protection was seen in infants younger than seven months or in any children later than six months after vaccination.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974386     DOI: 10.1093/clinids/3.supplement_1.s124

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  9 in total

1.  Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

Authors:  S C Szu; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

2.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

Review 3.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; E Saeland; S Gizurarson; D Schulz; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

5.  A brief history of pneumococcal vaccines.

Authors:  R Austrian
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

6.  Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

Authors:  C Chu; R Schneerson; J B Robbins; S C Rastogi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

7.  Current and Future Prospects for a Vaccine for Nontypeable Haemophilus influenzae.

Authors:  Timothy F Murphy
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725

8.  Humoral immune response in chinchillas to the capsular polysaccharides of Streptococcus pneumoniae.

Authors:  G S Giebink; G Schiffman
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

Review 9.  Otitis media with effusion: is medical management an option?

Authors:  P Burke
Journal:  J R Coll Gen Pract       Date:  1989-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.